Methylprednisolone
Depo-medrol, Medrol, Neo-medrol, Solu-medrol (methylprednisolone) is a small molecule pharmaceutical. Methylprednisolone was first approved as Medrol on 1982-01-01. It is used to treat adrenal insufficiency, ankylosing spondylitis, asthma, atopic dermatitis, and berylliosis amongst others in the USA. The pharmaceutical is active against glucocorticoid receptor. In addition, it is known to target short transient receptor potential channel 5.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Show 7 more
Trade Name
FDA
EMA
Depo-medrol, Medrol, Solu-medrol (generic drugs available since 1997-10-16, discontinued: A-methapred, M-predrol, Medrol)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone sodium succinate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SOLU-MEDROL | Pharmacia & Upjohn | N-011856 RX | 1982-01-01 | 5 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| dyural 40 kit | unapproved drug other | 2023-07-31 |
| dyural 80 kit | unapproved drug other | 2023-07-31 |
| dyural 80-lm | unapproved drug other | 2023-07-31 |
| dyural lm kit | unapproved drug other | 2022-12-09 |
| physicians ez use m-pred | unapproved drug other | 2023-07-19 |
| point of care lm dep 2 | ANDA | 2021-05-04 |
| readysharp anesthetics plus methylprednisolone 80 | New Drug Application | 2016-12-09 |
| readysharp-p40 | New Drug Application | 2016-12-13 |
| readysharp-p80 | New Drug Application | 2016-12-13 |
Indications
FDA
EMA
Show 18 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D07: Corticosteroids, dermatological preparations
— D07A: Corticosteroid dermatological preparations, plain
— D07AA: Corticosteroids, weak (group i)
— D07AA01: Methylprednisolone
— D07AC: Corticosteroids, potent (group iii)
— D07AC14: Methylprednisolone aceponate
— D07C: Corticosteroids, combinations with antibiotics
— D07CA: Corticosteroids, weak, combinations with antibiotics
— D07CA02: Methylprednisolone and antibiotics
— D10: Anti-acne preparations
— D10A: Anti-acne preparations for topical use
— D10AA: Corticosteroids, combinations for treatment of acne
— D10AA02: Methylprednisolone
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H02: Corticosteroids for systemic use
— H02A: Corticosteroids for systemic use, plain
— H02AB: Glucocorticoids, systemic
— H02AB04: Methylprednisolone
— H02B: Corticosteroids for systemic use, combinations
— H02BX: Corticosteroids for systemic use, combinations
— H02BX01: Methylprednisolone, combinations
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01C: Antiinflammatory agents and antiinfectives in combination
— S01CA: Corticosteroids and antiinfectives in combination, opthalmologic
— S01CA08: Methylprednisolone and antiinfectives
— S03: Ophthalmological and otological preparations
— S03C: Corticosteroids and antiinfectives in combination, opthalmologic and otologic
— S03CA: Corticosteroids and antiinfectives in combination
— S03CA07: Methylprednisolone and antiinfectives
HCPCS
Code | Description |
|---|---|
| J1020 | Injection, methylprednisolone acetate, 20 mg |
| J1030 | Injection, methylprednisolone acetate, 40 mg |
| J1040 | Injection, methylprednisolone acetate, 80 mg |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg |
| J7509 | Methylprednisolone oral, per 4 mg |
Clinical
Clinical Trials
2036 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 11 | 38 | 23 | 1 | 10 | 79 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 3 | 18 | 15 | 16 | 5 | 56 |
| Prostatic neoplasms | D011471 | — | C61 | 8 | 27 | 15 | 4 | 5 | 53 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 7 | 23 | 16 | 9 | 3 | 51 |
| Asthma | D001249 | EFO_0000270 | J45 | 2 | 5 | 9 | 15 | 12 | 43 |
| Kidney transplantation | D016030 | — | — | 1 | 11 | 12 | 17 | 2 | 42 |
| Covid-19 | D000086382 | — | U07.1 | 2 | 7 | 16 | 5 | 14 | 40 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 5 | 26 | 6 | 1 | — | 34 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 5 | 7 | 7 | 7 | 7 | 31 |
| Lupus nephritis | D008181 | EFO_0005761 | — | — | 12 | 9 | 4 | 4 | 29 |
Show 233 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 12 | 47 | 13 | — | 8 | 70 |
| Graft vs host disease | D006086 | — | D89.81 | 11 | 28 | 11 | — | 5 | 49 |
| Myelodysplastic syndromes | D009190 | — | D46 | 9 | 36 | 2 | — | 4 | 46 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 5 | 20 | 3 | — | 3 | 27 |
| Multiple myeloma | D009101 | — | C90.0 | 4 | 8 | 5 | — | 1 | 18 |
| Plasma cell neoplasms | D054219 | — | — | 3 | 9 | 2 | — | 4 | 18 |
| Alcoholic hepatitis | D006519 | EFO_1001345 | K70.1 | 1 | 6 | 7 | — | 5 | 18 |
| Hodgkin disease | D006689 | — | C81 | 2 | 10 | 4 | — | 1 | 16 |
| Hemophagocytic lymphohistiocytosis | D051359 | — | D76.1 | 1 | 2 | 8 | — | 4 | 14 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 6 | 11 | 2 | — | — | 14 |
Show 139 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloproliferative disorders | D009196 | — | D47.1 | 4 | 8 | — | — | 2 | 13 |
| Myelodysplastic-myeloproliferative diseases | D054437 | — | — | 1 | 8 | — | — | 2 | 11 |
| Fanconi anemia | D005199 | Orphanet_84 | D61.09 | 3 | 6 | — | — | 1 | 8 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 1 | 5 | — | — | — | 6 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 6 | — | — | — | 6 |
| Melanoma | D008545 | — | — | — | 4 | — | — | — | 4 |
| Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | 2 | 3 | — | — | — | 4 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | — | 4 | — | — | — | 4 |
| Digeorge syndrome | D004062 | — | D82.1 | 2 | 1 | — | — | 1 | 3 |
| Nasopharyngeal carcinoma | D000077274 | — | — | — | 3 | — | — | — | 3 |
Show 134 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Therapeutic equivalency | D013810 | — | — | 3 | — | — | — | — | 3 |
| Fever | D005334 | HP_0001945 | R50.9 | 1 | — | — | — | 1 | 2 |
| T-cell lymphoma | D016399 | — | — | 1 | — | — | — | — | 1 |
| T-cell leukemia | D015458 | — | — | 1 | — | — | — | — | 1 |
| Syndrome | D013577 | — | — | 1 | — | — | — | — | 1 |
| Lymphoid leukemia | D007945 | — | C91 | 1 | — | — | — | — | 1 |
| Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | — | — | 1 | — | — | — | — | 1 |
| Innate immunity | D007113 | — | — | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Raynaud disease | D011928 | EFO_1001145 | I73.0 | 1 | — | — | — | — | 1 |
Show 15 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Critical illness | D016638 | — | — | — | — | — | — | 3 | 3 |
| Intervertebral disc displacement | D007405 | EFO_1001800 | — | — | — | — | — | 3 | 3 |
| Insulin resistance | D007333 | HP_0000855 | E88.819 | — | — | — | — | 3 | 3 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 3 | 3 |
| Pathologic dilatation | D004108 | — | — | — | — | — | — | 3 | 3 |
| Regeneration | D012038 | — | — | — | — | — | — | 3 | 3 |
| Granulomatous mastitis | D058890 | — | N61.2 | — | — | — | — | 2 | 2 |
| Blood pressure | D001794 | EFO_0004325 | — | — | — | — | — | 2 | 2 |
| Vitiligo | D014820 | EFO_0004208 | L80 | — | — | — | — | 2 | 2 |
| Wound healing | D014945 | GO_0042060 | — | — | — | — | — | 2 | 2 |
Show 114 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Methylprednisolone |
| INN | methylprednisolone |
| Description | 6alpha-methylprednisolone is the 6alpha-stereoisomer of 6-methylprednisolone. It has a role as an anti-inflammatory drug, a neuroprotective agent, an antiemetic, an adrenergic agent, a xenobiotic and an environmental contaminant. It is a 6-methylprednisolone, a primary alpha-hydroxy ketone and a tertiary alpha-hydroxy ketone. |
| Classification | Small molecule |
| Drug class | steroids (not prednisolone derivatives); prednisone and prednisolone derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |
Identifiers
| PDB | — |
| CAS-ID | 83-43-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL650 |
| ChEBI ID | 6888 |
| PubChem CID | 6741 |
| DrugBank | DB00959 |
| UNII ID | X4W7ZR7023 (ChemIDplus, GSRS) |
Target
Agency Approved
NR3C1
NR3C1
Organism
Homo sapiens
Gene name
NR3C1
Gene synonyms
GRL
NCBI Gene ID
Protein name
glucocorticoid receptor
Protein synonyms
Nuclear receptor subfamily 3 group C member 1, nuclear receptor subfamily 3 group C member 1 variant hGR-B(54), nuclear receptor subfamily 3 group C member 1 variant hGR-B(77), nuclear receptor subfamily 3 group C member 1 variant hGR-B(93), nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
Uniprot ID
Mouse ortholog
Nr3c1 (14815)
glucocorticoid receptor (Q61629)
Alternate
TRPC5
TRPC5
Organism
Homo sapiens
Gene name
TRPC5
Gene synonyms
TRP5
NCBI Gene ID
Protein name
short transient receptor potential channel 5
Protein synonyms
hTRP-5, hTRP5, protein phosphatase 1, regulatory subunit 159, transient receptor potential channel 5, Transient receptor protein 5, TRP-5
Uniprot ID
Mouse ortholog
Trpc5 (22067)
short transient receptor potential channel 5 (Q9R0D4)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Medrol – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Methylprednisolone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 69,816 documents
View more details
Safety
Black-box Warning
Black-box warning for: Dyural 40 kit, Dyural 80 kit, Dyural 80-lm, Dyural lm kit, Physicians ez use m-pred
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
51,355 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use